At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 530 enrolled
Drug / intervention
Mirikizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1
In Brief
A Phase 3 clinical trial evaluating Mirikizumab and Placebo for Psoriasis. Completed, enrolled 530 participants across 69 sites in 9 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of mirikizumab in participants with moderate to severe plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesGermany, Japan, Mexico, Poland, Puerto Rico, Russia, South Korea, Taiwan, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedMar 2018
Enrollment StartApr 2018
Primary CompletionMar 2019
Study CompletionJan 2020
TodayJul 2026
First PostedMar 29, 2018
Enrollment StartApr 24, 2018
Primary CompletionMar 21, 2019
Study CompletionJan 16, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 8.3 years ago
Interventions
Mirikizumabdrug
Administered SC
Placebodrug
Administered SC